Top

Published in:

01-07-2019 | Ankylosing Spondylitis | Original Research

Serum Sclerostin and Bone Morphogenetic Protein-2 Levels in Patients with Ankylosing Spondylitis: A Meta-Analysis

Authors: Jiajia Yang, Shanshan Xu, Mengya Chen, Yaping Yuan, Xu Zhang, Yubo Ma, Meng Wu, Renfang Han, Xingxing Hu, Rui Liu, Jixiang Deng, Shiyang Guan, Xing Gao, Meijuan Pan, Shengqian Xu, Zongwen Shuai, Shanqun Jiang, Shihe Guan, Liwen Chen, Faming Pan

Published in: Calcified Tissue International | Issue 1/2019

Abstract

Various studies have investigated the serum sclerostin and bone morphogenetic protein-2 (BMP-2) levels in patients with ankylosing spondylitis (AS), but the results were inconsistent. The aim of this meta-analysis was to synthetically assess the associations of serum levels of sclerostin and BMP-2 with AS. Multiple electronic databases were searched to locate relevant articles published before November 2018. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by the random-effect model. Totally, 21 studies were included. Meta-analysis results showed no significant difference between AS group and control group in serum sclerostin levels (SMD = 0.098, 95% CI − 0.395 to 0.591, p = 0.697). Nevertheless, serum BMP-2 levels in AS patients were higher than that in controls (SMD = 1.184, 95% CI 0.209 to 2.159, p = 0.017). Subgroup analysis demonstrated that European and South American AS patients had lower serum levels of sclerostin than controls. AS patients with age ≥ 40 years, erythrocyte sedimentation rate (ESR) ≤ 20 mm/h and Bath Ankylosing Spondylitis Functional Index (BASFI) < 4 had statistically significant lower serum sclerostin concentrations compared to controls. Chinese and Korean AS patients as well as patients with lower CRP had higher serum BMP-2 levels than controls, and country may be a source of heterogeneity across the studies. No publication bias existed and sensitivity analysis confirmed the stability of results. Serum BMP-2, but not sclerostin levels may be closely related to the development of AS.

Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390. https://doi.org/10.1016/s0140-6736(07)60635-7 CrossRefPubMed

Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheumat Dis 69(8):1465–1470. https://doi.org/10.1136/ard.2009.124206 CrossRefPubMed

Perrotta FM, Ceccarelli F (2018) Serum sclerostin as a possible biomarker in ankylosing spondylitis: a case-control study. J Immunol Res. https://doi.org/10.1155/2018/9101964 CrossRefPubMedPubMedCentral

Liao HT, Lin YF, Tsai CY, Chou TC (2018) Bone morphogenetic proteins and Dickkopf-1 in ankylosing spondylitis. Scandin J Rheumatol 47(1):56–61. https://doi.org/10.1080/03009742.2017.1287305 CrossRef

Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87(2):99–107. https://doi.org/10.1007/s00223-010-9372-1 CrossRefPubMedPubMedCentral

Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148(6):2635–2643. https://doi.org/10.1210/en.2007-0270 CrossRefPubMed

Zhou Y, Wang T, Hamilton JL, Chen D (2017) Wnt/beta-catenin signaling in osteoarthritis and in other forms of arthritis. Curr Rheumatol Rep 19(9):53. https://doi.org/10.1007/s11926-017-0679-z CrossRefPubMedPubMedCentral

Lories RJ, Luyten FP (2007) Bone morphogenetic proteins in destructive and remodeling arthritis. Arthrit Res Therapy 9(2):207. https://doi.org/10.1186/ar2135 CrossRef

Hsu WK, Wang JC (2008) The use of bone morphogenetic protein in spine fusion. Spine J 8(3):419–425. https://doi.org/10.1016/j.spinee.2008.01.008 CrossRefPubMed

10.

Liu T, Gao Y, Sakamoto K, Minamizato T, Furukawa K, Tsukazaki T, Shibata Y, Bessho K, Komori T, Yamaguchi A (2007) BMP-2 promotes differentiation of osteoblasts and chondroblasts in Runx2-deficient cell lines. J Cell Physiol 211(3):728–735. https://doi.org/10.1002/jcp.20988 CrossRefPubMed

11.

Nakashima K, de Crombrugghe B (2003) Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet TIG 19(8):458–466. https://doi.org/10.1016/s0168-9525(03)00176-8 CrossRefPubMed

12.

Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Mineral Res 18(10):1842–1853. https://doi.org/10.1359/jbmr.2003.18.10.1842 CrossRef

13.

Fukuda T, Kokabu S, Ohte S, Sasanuma H, Kanomata K, Yoneyama K, Kato H, Akita M, Oda H, Katagiri T (2010) Canonical Wnts and BMPs cooperatively induce osteoblastic differentiation through a GSK3beta-dependent and beta-catenin-independent mechanism. Differentiation 80(1):46–52. https://doi.org/10.1016/j.diff.2010.05.002 CrossRefPubMed

14.

Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52(1):145–156. https://doi.org/10.1016/j.bone.2012.09.029 CrossRefPubMed

15.

Genre F, Rueda-Gotor J, Remuzgo-Martinez S, Corrales A, Ubilla B, Mijares V, Fernandez-Diaz C, Portilla V, Blanco R, Hernandez JL, Llorca J, Lopez-Mejias R, Gonzalez-Gay MA (2018) Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. Clin Exp Rheumatol 36(2):302–309. https://doi.org/10.3899/jrheum.170833 CrossRefPubMed

16.

Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, Gavana E, Sayegh FE (2017) Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Joint Bone Spine 84(3):309–315. https://doi.org/10.1016/j.jbspin.2016.05.008 CrossRefPubMed

17.

Xie Z, Wang P, Li Y, Deng W, Zhang X, Su H, Li D, Wu Y, Shen H (2016) Imbalance between bone morphogenetic protein 2 and noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis. Arthrit Rheumatol 68(2):430–440. https://doi.org/10.1002/art.39433 CrossRef

18.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed

19.

Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135 CrossRefPubMedPubMedCentral

20.

Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 27(6):1785–1805. https://doi.org/10.1177/0962280216669183 CrossRefPubMed

21.

Sun W, Tian L, Jiang L, Zhang S, Zhou M, Zhu J, Xue J (2018) Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis. Clin Rheumatol. https://doi.org/10.1007/s10067-018-4356-z CrossRefPubMed

22.

Luchetti MM, Ciccia F, Avellini C, Benfaremo D, Guggino G, Farinelli A, Ciferri M, Rossini M, Svegliati S, Spadoni T, Bolognini L, Fava G, Mosca P, Gesuita R, Skrami E, Triolo G, Gabrielli A (2018) Sclerostin and anti sclerostin antibody serum levels predict the presence of axial spondyloarthritis in patients with inflammatory bowel disease. J Immunol Res 45(5):630–637. https://doi.org/10.1155/2018/910196410.3899/jrheum.170833 CrossRef

23.

Niu CC, Lin SS, Yuan LJ, Chen LH, Yang CY, Chung AN, Lu ML, Tsai TT, Lai PL, Chen WJ (2017) Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. BMC musculoskeletal disorders 18(1):61. https://doi.org/10.1186/s12891-017-1425-4 CrossRefPubMedPubMedCentral

24.

Tian L, Zhou M, Zhang S, Xue J (2017) Correlation analysis of serum osteotin level and bone imaging changes in patients with ankylosing spondylitis. Zhejiang clinical medicine 19(8):1394–1396

25.

Lu Z, Guan Z (2017) Serum levels of Dickkopf-1, sclerostin and vascular endothelial growth factor A and their correlation with ankylosing spondylitis progression. Chin J Tissue Eng Res 21(32):5085–5090

26.

Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, Povino MR, Kunnathully V, Adami S, Gatti D (2016) Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int 98(5):438–445. https://doi.org/10.1007/s00223-015-0093-3 CrossRefPubMed

27.

Xie J, Yu X (2015) [Correlation between sclerostin level and radiographic changes in patients with ankylosing spondylitis]. Zhonghua yi xue za zhi 95(17):1300–1304PubMed

28.

Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41(7):1349–1356. https://doi.org/10.3899/jrheum.131199 CrossRefPubMed

29.

Tuylu T, Sari I, Solmaz D, Kozaci DL, Akar S, Gunay N, Onen F, Akkoc N (2014) Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study. Clinics (Sao Paulo Brazil) 69(10):688–693. https://doi.org/10.6061/clinics/2014(10)07 CrossRef

30.

Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD (2014) Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol port 39(2):146–151PubMed

31.

Korkosz M, Gasowski J, Leszczynski P, Pawlak-Bus K, Jeka S, Kucharska E, Grodzicki T (2013) High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord 14:99. https://doi.org/10.1186/1471-2474-14-99 CrossRefPubMedPubMedCentral

32.

Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N (2012) Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 13:191. https://doi.org/10.1186/1471-2474-13-191 CrossRefPubMedPubMedCentral

33.

Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB, de Oliveira RM, Silva CA, Bonfa E, Pereira RM (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Therapy 14(5):R216. https://doi.org/10.1186/ar4055 CrossRef

34.

Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60(11):3257–3262. https://doi.org/10.1002/art.24888 CrossRefPubMed

35.

Chen HA, Chen CH, Lin YJ, Chen PC, Chen WS, Lu CL, Chou CT (2010) Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol 37(10):2126–2132. https://doi.org/10.3899/jrheum.100200 CrossRefPubMed

36.

Park MC, Park YB, Lee SK (2008) Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol 37(3):200–204. https://doi.org/10.1080/03009740701774941 CrossRefPubMed

37.

Chen Z, Wang S, Zhu G (2015) The relationship between serum ossification and mSASSS score in ankylosing spondylitis patients. World Latest Med Inf 15(83):1–3

38.

Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747–783. https://doi.org/10.1210/er.2011-1060 CrossRefPubMed

39.

Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ (2014) Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone 67:305–313. https://doi.org/10.1016/j.bone.2014.07.031 CrossRefPubMed

40.

Wildemann B, Burkhardt N, Luebberstedt M, Vordemvenne T, Schmidmaier G (2007) Proliferating and differentiating effects of three different growth factors on pluripotent mesenchymal cells and osteoblast like cells. J Orthop Surg Res 2:27. https://doi.org/10.1186/1749-799x-2-27 CrossRefPubMedPubMedCentral

41.

Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127(6 Pt 1):1755–1766CrossRefPubMed

42.

Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, Stone MA, Corr M, Gensler LS, Gladman D, Morgan A, Marzo-Ortega H, Ward MM, Learch TJ, Reveille JD, Brown MA, Weisman MH (2015) Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis 74(7):1387–1393. https://doi.org/10.1136/annrheumdis-2013-204835 CrossRefPubMed

43.

Shi J, Ying H, Du J, Shen B (2017) Serum sclerostin levels in patients with ankylosing spondylitis and rheumatoid arthritis: a systematic review and meta-analysis. Biomed Res Int 2017:9295313. https://doi.org/10.1155/2017/9295313 CrossRefPubMedPubMedCentral

44.

Koide M, Kobayashi Y (2018) Regulatory mechanisms of sclerostin expression during bone remodeling. J Bone Miner Metab. https://doi.org/10.1007/s00774-018-0971-7 CrossRefPubMed

45.

Zhang L, Ouyang H, Xie Z, Liang ZH, Wu XW (2016) Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis. Exp Mol Med 48:e228. https://doi.org/10.1038/emm.2016.12 CrossRefPubMedPubMedCentral

46.

Zou YC, Yang XW, Yuan SG, Zhang P, Ye YL, Li YK (2016) Downregulation of dickkopf-1 enhances the proliferation and osteogenic potential of fibroblasts isolated from ankylosing spondylitis patients via the Wnt/beta-catenin signaling pathway in vitro. Connect Tissue Res 57(3):200–211. https://doi.org/10.3109/03008207.2015.1127916 CrossRefPubMed

47.

Wu M, Chen M, Ma Y, Yang J, Han R, Yuan Y, Hu X, Wang M, Zhang X, Xu S, Liu R, Jiang G, Xu J, Shuai Z, Zou Y, Pan G, Pan F (2018) Dickkopf-1 in ankylosing spondylitis: Review and meta-analysis. Clin Chim Acta 481:177–183. https://doi.org/10.1016/j.cca.2018.03.010 CrossRefPubMed

48.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163. https://doi.org/10.1038/nm1538 CrossRefPubMed

49.

Kuipers AL, Zhang Y, Yu S, Kammerer CM, Nestlerode CS, Chu Y, Bunker CH, Patrick AL, Wheeler VW, Miljkovic I, Zmuda JM (2014) Relative influence of heritability, environment and genetics on serum sclerostin. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. Osteoporos Int 25 (3):905–912. https://doi.org/10.1007/s00198-013-2517-0 CrossRefPubMed

50.

Luchetti MM, Ciccia F, Avellini C, Benfaremo D, Guggino G, Farinelli A, Ciferri M, Rossini M, Svegliati S, Spadoni T, Bolognini L, Fava G, Mosca P, Gesuita R, Skrami E, Triolo G, Gabrielli A (2018) Sclerostin and antisclerostin antibody serum levels predict the presence of axial spondyloarthritis in patients with inflammatory bowel disease. J Rheumatol 45(5):630–637. https://doi.org/10.3899/jrheum.170833 CrossRefPubMed

51.

Pietrzyk B, Wyskida K, Ficek J, Kolonko A, Ficek R, Wiecek A, Olszanecka-Glinianowicz M, Chudek J (2018) Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. Int Urol Nephrol. https://doi.org/10.1007/s11255-018-2050-3 CrossRefPubMedPubMedCentral

52.

Almroth G, Lonn J, Uhlin F, Brudin L, Andersson B, Hahn-Zoric M (2016) Sclerostin, TNF-alpha and Interleukin-18 correlate and are together with Klotho related to other growth factors and cytokines in haemodialysis patients. Scand J Immunol 83(1):58–63. https://doi.org/10.1111/sji.12392 CrossRefPubMed

53.

Croft M, Siegel RM (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol 13(4):217–233. https://doi.org/10.1038/nrrheum.2017.22 CrossRefPubMedPubMedCentral

54.

Li SS (2017) Mechanisms underlying the post-transcriptional regulation of murine sclerostin by TNF-alpha. Thesis of master, Shandong university

55.

Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed

56.

Li Q, Li L, Bi L, Xiao C, Lin Z, Cao S, Liao Z, Gu J (2016) Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial. Trials 17(1):337. https://doi.org/10.1186/s13063-016-1438-6 CrossRefPubMedPubMedCentral

57.

Zong HX, Xu SQ, Tong H, Wang XR, Pan MJ, Teng YZ (2018) Effect of anti-tumor necrosis factor alpha treatment on radiographic progression in patient with ankylosing spondylitis: a systematic review and meta-analysis. Mod Rheumatol. https://doi.org/10.1080/14397595.2018.1525017 CrossRef

58.

Muntean L, Lungu A, Gheorghe SR, Valeanu M, Craciun AM, Felea I, Petcu A, Filipescu I, Simon SP, Rednic S (2016) Elevated serum levels of sclerostin are associated with high disease activity and functional impairment in patients with axial spondyloarthritis. Clin Lab 62(4):589–597PubMed

59.

Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98(9):3873–3883. https://doi.org/10.1210/jc.2013-2113 CrossRefPubMed

60.

Piec I, Washbourne C, Tang J, Fisher E, Greeves J, Jackson S, Fraser WD (2016) How accurate is your sclerostin measurement? Comparison between three commercially available sclerostin ELISA kits. Calcif Tissue Int 98(6):546–555. https://doi.org/10.1007/s00223-015-0105-3 CrossRefPubMedPubMedCentral

61.

Liu Y, Hou R, Yin R, Yin W (2015) Correlation of bone morphogenetic protein-2 levels in serum and synovial fluid with disease severity of knee osteoarthritis. Med Sci Monit. 21:363–370. https://doi.org/10.12659/msm.892160 CrossRefPubMedPubMedCentral

62.

Chemel M, Brion R, Segaliny AI, Lamora A, Charrier C, Brulin B, Maugars Y, Le Goff B, Heymann D, Verrecchia F (2017) Bone morphogenetic protein 2 and transforming growth factor beta1 inhibit the expression of the proinflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts. Am J Pathol 187(1):156–162. https://doi.org/10.1016/j.ajpath.2016.09.015 CrossRefPubMed

63.

Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL (2005) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64(1):127–129. https://doi.org/10.1136/ard.2004.020503 CrossRefPubMed

64.

Deminger A, Klingberg E, Geijer M, Gothlin J, Hedberg M, Rehnberg E, Carlsten H, Jacobsson LT, Forsblad-d’Elia H (2018) A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis. Arthritis Res Therapy 20(1):162. https://doi.org/10.1186/s13075-018-1665-1 CrossRef

65.

Ramiro S, Landewe R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D (2015) Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 1(1):e000153. https://doi.org/10.1136/rmdopen-2015-000153 CrossRefPubMedPubMedCentral

66.

Maas F, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, Spoorenberg A (2017) Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PloS ONE 12(6):e0177231. https://doi.org/10.1371/journal.pone.0177231 CrossRefPubMedPubMedCentral

Title: Serum Sclerostin and Bone Morphogenetic Protein-2 Levels in Patients with Ankylosing Spondylitis: A Meta-Analysis
Authors: Jiajia Yang
Shanshan Xu
Mengya Chen
Yaping Yuan
Xu Zhang
Yubo Ma
Meng Wu
Renfang Han
Xingxing Hu
Rui Liu
Jixiang Deng
Shiyang Guan
Xing Gao
Meijuan Pan
Shengqian Xu
Zongwen Shuai
Shanqun Jiang
Shihe Guan
Liwen Chen
Faming Pan
Publication date: 01-07-2019
Publisher: Springer US
Keyword: Ankylosing Spondylitis
Published in: Calcified Tissue International / Issue 1/2019
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-019-00542-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture

Clinical Manifestations and Factors Associated with Osteosarcopenic Obesity Syndrome: A Cross-Sectional Study in Koreans with Obesity

Associations of Sarcopenia and Its Components with Bone Structure and Incident Falls in Swedish Older Adults

Insulin-Like Growth Factor-I Protects Against the Detrimental Effects of Advanced Glycation End Products and High Glucose in Myoblastic C2C12 Cells

Paget’s Disease of Long Bones: Microstructural Analyses of Historical Bone Samples

Regional Changes in Density and Microarchitecture in the Ultradistal Tibia of Female Recruits After U.S. Army Basic Combat Training

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage